
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2303875/publications.pdf Version: 2024-02-01



FLAVIO NOBILI

#	Article	IF	CITATIONS
1	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.4	24
2	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 563-584.	3.3	41
3	Stratification Tools for Diseaseâ€Modifying Trials in Prodromal Synucleinopathy. Movement Disorders, 2022, 37, 52-61.	2.2	7
4	Phase and amplitude electroencephalography correlations change with disease progression in people with idiopathic rapid eye-movement sleep behavior disorder. Sleep, 2022, 45, .	0.6	3
5	Resting State Alpha Electroencephalographic Rhythms Are Affected by Sex in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment: A Retrospective and Exploratory Study. Cerebral Cortex, 2022, 32, 2197-2215.	1.6	8
6	Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1263-1274.	3.3	12
7	Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson's disease (PD) do not overlap. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1939.	3.3	11
8	The Role of Hub and Spoke Regions in Theory of Mind in Early Alzheimer's Disease and Frontotemporal Dementia. Biomedicines, 2022, 10, 544.	1.4	8
9	Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases. Neurobiology of Aging, 2022, 115, 88-108.	1.5	11
10	The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort. Journal of Alzheimer's Disease, 2022, 87, 887-899.	1.2	1
11	Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data. Neurobiology of Aging, 2022, 117, 212-221.	1.5	4
12	Alzheimer's Disease with Epileptiform EEG Activity: Abnormal Cortical Sources of Resting State Delta Rhythms in Patients with Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2022, , 1-29.	1.2	2
13	B Lymphocytes in Alzheimer's Disease—A Comprehensive Review. Journal of Alzheimer's Disease, 2022, 88, 1241-1262.	1.2	5
14	The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 1945-1955.	1.5	1
15	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. Magnetic Resonance Imaging, 2021, 76, 108-115.	1.0	24
16	Rapid eye movement sleep behavior disorder: A proofâ€ofâ€concept neuroprotection study for prodromal synucleinopathies. European Journal of Neurology, 2021, 28, 1210-1217.	1.7	9
17	Abnormalities of Cortical Sources of Resting State Alpha Electroencephalographic Rhythms are Related to Education Attainment in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment. Cerebral Cortex, 2021, 31, 2220-2237.	1.6	14
18	Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain, 2021, 144, 278-287.	3.7	68

#	Article	IF	CITATIONS
19	Stacked autoencoders as new models for an accurate Alzheimer's disease classification support using resting-state EEG and MRI measurements. Clinical Neurophysiology, 2021, 132, 232-245.	0.7	30
20	Biomarker counseling, disclosure of diagnosis and followâ€up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. International Journal of Geriatric Psychiatry, 2021, 36, 324-333.	1.3	19
21	Validation of FDG-PET datasets of normal controls for the extraction of SPM-based brain metabolism maps. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2486-2499.	3.3	21
22	Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2834-2845.	3.3	22
23	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A Europeanâ€ÐLB consortium project. Alzheimer's and Dementia, 2021, 17, 1277-1286.	0.4	5
24	A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer's Disease in Subjects with Mild Cognitive Impairment. Current Alzheimer Research, 2021, 17, 1186-1194.	0.7	4
25	Brain Metabolic Correlates of Persistent Olfactory Dysfunction after SARS-Cov2 Infection. Biomedicines, 2021, 9, 287.	1.4	39
26	Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies. Brain Communications, 2021, 3, fcab045.	1.5	37
27	The fate of patients with REM sleep behavior disorder and mild cognitive impairment. Sleep Medicine, 2021, 79, 205-210.	0.8	19
28	Probing the Role of a Regional Quantitative Assessment of Amyloid PET. Journal of Alzheimer's Disease, 2021, 80, 383-396.	1.2	3
29	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. Alzheimer's and Dementia, 2021, 17, 1528-1553.	0.4	64
30	Is the Frontal Lobe the Primary Target of SARS-CoV-2?. Journal of Alzheimer's Disease, 2021, 81, 75-81.	1.2	39
31	Dopaminergic and Serotonergic Degeneration and Cortical [ 18 F ]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease. Movement Disorders, 2021, 36, 2293-2302.	2.2	7
32	FDG PET Unveils the Course of Paraneoplastic Cerebellar Degeneration. Clinical Nuclear Medicine, 2021, 46, e327-e328.	0.7	3
33	From early limbic inflammation to long COVID sequelae. Brain, 2021, 144, e65-e65.	3.7	14
34	EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel. Neurobiology of Aging, 2021, 103, 78-97.	1.5	9
35	Dementia and COVID-19, a Bidirectional Liaison: Risk Factors, Biomarkers, and Optimal Health Care. Journal of Alzheimer's Disease, 2021, 82, 883-898.	1.2	48
36	Resting State Alpha Electroencephalographic Rhythms Are Differently Related to Aging in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 82, 1085-1114.	1.2	8

#	Article	IF	CITATIONS
37	Polysomnographic correlates of sleep disturbances in de novo, drug naÃ⁻ve Parkinson's Disease. Neurological Sciences, 2021, , 1.	0.9	2
38	Sex differences in neuroimaging biomarkers in healthy subjects and dementia. , 2021, , 125-162.		0
39	Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD). Diagnostics, 2021, 11, 108.	1.3	3
40	Alzheimer's disease MRI patterns: Cognitive, structural and cerebrospinal fluid correlates. Journal of the Neurological Sciences, 2021, 429, 119006.	0.3	0
41	Evaluation of Age and Sex-Related Metabolic Changes in Healthy Subjects: An Italian Brain 18F-FDG PET Study. Journal of Clinical Medicine, 2021, 10, 4932.	1.0	1
42	Neuroimaging Findings in Mild Cognitive Impairment. , 2021, , 367-425.		1
43	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiology of Aging, 2020, 85, 58-73.	1.5	150
44	Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD. Journal of the American Medical Directors Association, 2020, 21, 194-200.	1.2	21
45	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 270-280.	3.3	23
46	Italian consensus recommendations for a biomarkerâ€based aetiological diagnosis in mild cognitive impairment patients. European Journal of Neurology, 2020, 27, 475-483.	1.7	20
47	Metabolic Network Abnormalities in Drugâ€NaÃ⁻ve Parkinson's Disease. Movement Disorders, 2020, 35, 587-594.	2.2	19
48	Clinical and MRI Predictors of Conversion From Mild Behavioural Impairment to Dementia. American Journal of Geriatric Psychiatry, 2020, 28, 755-763.	0.6	19
49	CSF cutoffs for MCI due to AD depend on APOEε4 carrier status. Neurobiology of Aging, 2020, 89, 55-62.	1.5	11
50	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. Movement Disorders, 2020, 35, 595-605.	2.2	42
51	Abnormal pattern of brain glucose metabolism in Parkinson's disease: replication in three European cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 437-450.	3.3	54
52	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	4.9	254
53	The role of anterior prefrontal cortex in prospective memory: an exploratory FDG-PET study in early Alzheimer's disease. Neurobiology of Aging, 2020, 96, 117-127.	1.5	11
54	Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms. Clinical Neurophysiology, 2020, 131, 2716-2731.	0.7	11

#	Article	IF	CITATIONS
55	Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease. Cortex, 2020, 130, 401-412.	1.1	16
56	Abnormalities of Cortical Sources of Resting State Delta Electroencephalographic Rhythms Are Related to Epileptiform Activity in Patients With Amnesic Mild Cognitive Impairment Not Due to Alzheimer's Disease. Frontiers in Neurology, 2020, 11, 514136.	1.1	8
57	Multicenter Study on Sleep and Circadian Alterations as Objective Markers of Mild Cognitive Impairment and Alzheimer's Disease Reveals Sex Differences. Journal of Alzheimer's Disease, 2020, 78, 1707-1719.	1.2	20
58	Resting-state electroencephalographic delta rhythms may reflect global cortical arousal in healthy old seniors and patients with Alzheimer's disease dementia. International Journal of Psychophysiology, 2020, 158, 259-270.	0.5	14
59	Sedative Load in Community-Dwelling Older Adults with Mild–Moderate Alzheimer's Disease: Longitudinal Relationships with Adverse Events, Delirium and Falls. Drugs and Aging, 2020, 37, 829-837.	1.3	5
60	Amygdalar nuclei and hippocampal subfields on MRI: Testâ€retest reliability of automated segmentation in old and young healthy volunteers. Alzheimer's and Dementia, 2020, 16, e040322.	0.4	0
61	18F-Fluorodeoxyglucose Positron Emission Tomography Tracks the Heterogeneous Brain Susceptibility to the Hyperglycemia-Related Redox Stress. International Journal of Molecular Sciences, 2020, 21, 8154.	1.8	6
62	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. NeuroImage, 2020, 218, 116932.	2.1	38
63	Serum adiponectin levels are associated with presence of carotid plaque in women with systemic lupus erythematosus. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1147-1151.	1.1	4
64	Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. Neurobiology of Aging, 2020, 91, 88-111.	1.5	24
65	Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis: a computational approach to [18F]-fluorodeoxyglucose PET/CT images. EJNMMI Research, 2020, 10, 23.	1.1	17
66	A kinetics-based approach to amyloid PET semi-quantification. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2175-2185.	3.3	3
67	Epilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study. Journal of Alzheimer's Disease, 2020, 74, 865-874.	1.2	21
68	Anterior EEG slowing in dementia with Lewy bodies: a multicenter European cohort study. Neurobiology of Aging, 2020, 93, 55-60.	1.5	14
69	Utility of quantitative EEG in early Lewy body disease. Parkinsonism and Related Disorders, 2020, 75, 70-75.	1.1	27
70	Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. Lancet Neurology, The, 2020, 19, 699-710.	4.9	96
71	Biomarker Testing: Piercing the Fog of Alzheimer's and Related Dementia. Biomedicine Hub, 2020, 5, 1-22.	0.4	7
72	Striatal dopamine transporter SPECT quantification: head-to-head comparison between two three-dimensional automatic tools. EJNMMI Research, 2020, 10, 137.	1.1	6

#	Article	IF	CITATIONS
73	123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies. European Radiology Experimental, 2020, 4, 27.	1.7	2
74	Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. Journal of Alzheimer's Disease, 2019, 69, 3-14.	1.2	18
75	Cortical Network Topology in Prodromal and Mild Dementia Due to Alzheimer's Disease: Graph Theory Applied to Resting State EEG. Brain Topography, 2019, 32, 127-141.	0.8	40
76	Cognitive impairment in late life bipolar disorder: Risk factors and clinical outcomes. Journal of Affective Disorders, 2019, 257, 166-172.	2.0	19
77	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. Alzheimer's Research and Therapy, 2019, 11, 74.	3.0	28
78	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	4.9	85
79	FDC-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology, 2019, 92, e1121-e1135.	1.5	63
80	Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases. Neurobiology of Aging, 2019, 77, 112-127.	1.5	33
81	Blood Pressure Lowering With Nilvadipine in Patients With Mildâ€toâ€Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. Journal of the American Heart Association, 2019, 8, e011938.	1.6	10
82	Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1642-1651.	3.3	38
83	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). Neurolmage: Clinical, 2019, 23, 101846.	1.4	18
84	Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 6.	1.8	29
85	Could arterial spin labelling perfusion imaging uncover the invisible in <i>N</i> â€methylâ€ <scp>d</scp> â€aspartate receptor encephalitis?. European Journal of Neurology, 2019, 26, e86-e87.	1.7	7
86	Scaled Subprofile Modeling and Convolutional Neural Networks for the Identification of Parkinson's Disease in 3D Nuclear Imaging Data. International Journal of Neural Systems, 2019, 29, 1950010.	3.2	48
87	18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease. , 2019, , 37-48.		1
88	The role of molecular imaging in the frame of the revised dementia with Lewy body criteria. Clinical and Translational Imaging, 2019, 7, 83-98.	1.1	1
89	Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 49-58.	1.2	8
90	Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study. Journal of Neurology, 2019, 266, 1633-1642.	1.8	25

#	Article	IF	CITATIONS
91	Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain, 2019, 142, 744-759.	3.7	636
92	Metabolic patterns across core features in dementia with lewy bodies. Annals of Neurology, 2019, 85, 715-725.	2.8	47
93	Brain Glucose Metabolism Heterogeneity in Idiopathic REM Sleep Behavior Disorder and in Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 229-239.	1.5	12
94	Serum osteopontin negatively impacts on intimaâ€media thickness in patients with systemic lupus erythematosus. European Journal of Clinical Investigation, 2019, 49, e13089.	1.7	8
95	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease1. Journal of Alzheimer's Disease, 2019, 68, 383-394.	1.2	14
96	Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker. Journal of Alzheimer's Disease, 2019, 72, 1193-1207.	1.2	5
97	Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. Journal of Alzheimer's Disease, 2019, 69, 37-48.	1.2	23
98	Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms. Neurobiology of Aging, 2019, 73, 9-20.	1.5	26
99	Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. Neurobiology of Aging, 2019, 76, 9-17.	1.5	23
100	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Journal of Alzheimer's Disease, 2019, 69, 15-35.	1.2	34
101	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. Alzheimer's and Dementia, 2019, 15, 400-409.	0.4	60
102	Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 334-347.	3.3	20
103	A new frontier for amyloid PET imaging: multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 276-279.	3.3	7
104	Serum neurofilament light chain rate of change in Alzheimer's disease: potentials applications and notes of caution. Annals of Translational Medicine, 2019, 7, S133-S133.	0.7	8
105	Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 83-92.	0.4	0
106	Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases. Journal of Alzheimer's Disease, 2018, 62, 247-268.	1.2	50
107	The Metabolic Pattern of Idiopathic REM Sleep Behavior Disorder Reflects Early-Stage Parkinson Disease. Journal of Nuclear Medicine, 2018, 59, 1437-1444.	2.8	80
108	Presynaptic dopaminergic neuroimaging in REM sleep behavior disorder: A systematic review and meta-analysis. Sleep Medicine Reviews, 2018, 41, 266-274.	3.8	56

#	Article	IF	CITATIONS
109	The clinical relevance of cognitive impairment in REM sleep behavior disorder. Neurology, 2018, 90, 909-910.	1.5	4
110	FDC-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. NeuroImage: Clinical, 2018, 18, 167-177.	1.4	108
111	Functional cortical source connectivity of resting state electroencephalographic alpha rhythms shows similar abnormalities in patients with mild cognitive impairment due to Alzheimer's and Parkinson's diseases. Clinical Neurophysiology, 2018, 129, 766-782.	0.7	45
112	Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. Neurobiology of Aging, 2018, 65, 18-40.	1.5	61
113	Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD). Alzheimer's Research and Therapy, 2018, 10, 35.	3.0	22
114	Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1557-1566.	3.3	35
115	Assessing FDC-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1470-1486.	3.3	19
116	Clinical utility of FDC-PET in amyotrophic lateral sclerosis and Huntington's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1546-1556.	3.3	24
117	Brain FDG-PET: clinical use in dementing neurodegenerative conditions. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1467-1469.	3.3	2
118	Integrating Sleep and Alzheimer's Disease Pathophysiology: Hints for Sleep Disorders Management. Journal of Alzheimer's Disease, 2018, 63, 871-886.	1.2	20
119	Clinical utility of FDC-PET for the clinical diagnosis in MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1497-1508.	3.3	61
120	Effect of starvation on brain glucose metabolism and 18F-2-fluoro-2-deoxyglucose uptake: an experimental in-vivo and ex-vivo study. EJNMMI Research, 2018, 8, 44.	1.1	14
121	Longitudinal brain magnetic resonance imaging and realâ€ŧime quaking induced conversion analysis in presymptomatic Creutzfeldt–Jakob disease. European Journal of Neurology, 2018, 25, e127-e128.	1.7	10
122	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Medicine, 2018, 15, e1002660.	3.9	131
123	Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1534-1545.	3.3	86
124	Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1487-1496.	3.3	35
125	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain <sup>18</sup> Fâ€fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. European Journal of Neurology. 2018, 25, 1201-1217.	1.7	153
126	Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis. Brain, 2018, 141, 2272-2279.	3.7	33

#	Article	IF	CITATIONS
127	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1509-1525.	3.3	81
128	Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1526-1533.	3.3	28
129	Different Abnormalities of Cortical Neural Synchronization Mechanisms in Patients with Mild Cognitive Impairment due to Alzheimer's and Chronic Kidney Diseases: An EEG Study. Journal of Alzheimer's Disease, 2018, 65, 897-915.	1.2	12
130	New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases. Current Medicinal Chemistry, 2018, 25, 3105-3130.	1.2	14
131	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
132	Progressive Disintegration of Brain Networking from Normal Aging to Alzheimer Disease: Analysis of Independent Components of <sup>18</sup> F-FDG PET Data. Journal of Nuclear Medicine, 2017, 58, 1132-1139.	2.8	41
133	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. Alzheimer's and Dementia, 2017, 13, 1013-1023.	0.4	33
134	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiology of Aging, 2017, 53, 1-10.	1.5	59
135	Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. Neurobiology of Aging, 2017, 55, 143-158.	1.5	76
136	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	1.5	27
137	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. Journal of Alzheimer's Disease, 2017, 57, 787-795.	1.2	69
138	Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 183-195.	1.5	85
139	Clinical validity of presynaptic dopaminergic imaging withÂ123I-ioflupaneÂand noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 228-242.	1.5	34
140	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 214-227.	1.5	67
141	Homonymous hemianopia as the first sign of posterior cortical atrophy. Journal of the Neurological Sciences, 2017, 373, 38-40.	0.3	5
142	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1387-1395.	1.2	24
143	Abnormalities of Cortical Neural Synchronization Mechanisms in Subjects with Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases: An EEG Study. Journal of Alzheimer's Disease, 2017, 59, 339-358.	1.2	45
144	Effectiveness of Florbetapir PET Imaging in Changing Patient Management. Dementia and Geriatric Cognitive Disorders, 2017, 44, 129-143.	0.7	35

#	Article	IF	CITATIONS
145	The Alzheimer's disease metabolic brain pattern in mild cognitive impairment. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3643-3648.	2.4	29
146	18F–FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2073-2083.	3.3	29
147	Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers. Movement Disorders, 2017, 32, 1738-1747.	2.2	43
148	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	4.9	464
149	Early identification of MCI converting to AD: a FDG PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2042-2052.	3.3	83
150	Free water elimination improves test–retest reproducibility of diffusion tensor imaging indices in the brain: A longitudinal multisite study of healthy elderly subjects. Human Brain Mapping, 2017, 38, 12-26.	1.9	72
151	The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. Neurological Sciences, 2017, 38, 83-91.	0.9	11
152	Learning "How to Learn― Super Declarative Motor Learning Is Impaired in Parkinson's Disease. Neural Plasticity, 2017, 2017, 1-8.	1.0	8
153	Functional/structural neuroimaging as a "unique" science. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 341-344.	0.4	1
154	Clinical utility and research frontiers of neuroimaging in movement disorders. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 372-385.	0.4	3
155	Classification of Single Normal and Alzheimer's Disease Individuals from Cortical Sources of Resting State EEG Rhythms. Frontiers in Neuroscience, 2016, 10, 47.	1.4	73
156	Frontal Variant Alzheimer Disease or Frontotemporal Lobe Degeneration With Incidental Amyloidosis?. Alzheimer Disease and Associated Disorders, 2016, 30, 183-185.	0.6	8
157	Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a â€ <sup>~</sup> European <scp>ADNI</scp> study'. Journal of Internal Medicine, 2016, 279, 576-591.	2.7	64
158	EEG Markers of Dementia with Lewy Bodies: A Multicenter Cohort Study. Journal of Alzheimer's Disease, 2016, 54, 1649-1657.	1.2	47
159	Agomelatine Improves Apathy in Frontotemporal Dementia. Neurodegenerative Diseases, 2016, 16, 352-356.	0.8	37
160	Mapping brain morphological and functional conversion patterns in predementia late-onset bvFTD. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1337-1347.	3.3	27
161	<sup>123</sup> lâ€2βâ€carbomethoxyâ€3βâ€(4â€iodophenyl)â€ <i>N</i> â€(3â€fluoropropyl) nortropane sing emission computed tomography and <sup>123</sup> lâ€metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study. Annals of Neurology. 2016. 80. 368-378.	le photon 2.8	42
162	Predicting the transition from normal aging to Alzheimer's disease: A statistical mechanistic evaluation of FDG-PET data. NeuroImage, 2016, 141, 282-290.	2.1	36

#	Article	IF	CITATIONS
163	Standardized Uptake Value Ratio-Independent Evaluation of Brain Amyloidosis. Journal of Alzheimer's Disease, 2016, 54, 1437-1457.	1.2	22
164	A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2061-2071.	3.3	27
165	Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. Human Brain Mapping, 2016, 37, 2114-2132.	1.9	38
166	Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson's disease and probable RBD. Parkinsonism and Related Disorders, 2016, 29, 47-53.	1.1	57
167	ls dopamine transporter invariably impaired at the time of diagnosis in dementia with Lewy bodies?. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1056-1059.	3.3	9
168	Baseline CSF Aβ, Aβ/T-TAU and Aβ/P-tau distributions to classify pharmacog MCI patients. Neurobiology of Aging, 2016, 39, S30.	1.5	0
169	Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis. Human Brain Mapping, 2016, 37, 942-953.	1.9	40
170	Parkinson's Disease Sleep Scale 2: application in an Italian population. Neurological Sciences, 2016, 37, 283-288.	0.9	21
171	Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline. Neurological Sciences, 2016, 37, 227-234.	0.9	9
172	An updated Italian normative dataset for the Stroop color word test (SCWT). Neurological Sciences, 2016, 37, 365-372.	0.9	49
173	Reduction in camera-specific variability in [123I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1323-1336.	3.3	35
174	Implementation of the European multicentre database of healthy controls for [1231]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1315-1322.	3.3	29
175	The prognostic value of sleep patterns in disorders of consciousness in the sub-acute phase. Clinical Neurophysiology, 2016, 127, 1445-1451.	0.7	52
176	Integrating longitudinal information in hippocampal volume measurements for the early detection of Alzheimer's disease. Neurolmage, 2016, 125, 834-847.	2.1	76
177	Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study. NeuroImage, 2016, 124, 442-454.	2.1	85
178	Classification of Healthy Subjects and Alzheimer's Disease Patients with Dementia from Cortical Sources of Resting State EEG Rhythms: A Study Using Artificial Neural Networks. Frontiers in Neuroscience, 2016, 10, 604.	1.4	51
179	Neurophysiological Assessment of Alzheimer's Disease Individuals by a Single Electroencephalographic Marker. Journal of Alzheimer's Disease, 2015, 49, 159-177.	1.2	32
180	The Role of the Serotonergic System in REM Sleep Behavior Disorder. Sleep, 2015, 38, 1505-1509.	0.6	36

#	Article	IF	CITATIONS
181	Late Persistent Increased Putaminal 18F-DOPA Uptake Following Ipsilateral Frontal Resection. Clinical Nuclear Medicine, 2015, 40, e451-e452.	0.7	5
182	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite <scp>E</scp> uropean 3T study on healthy elderly. Human Brain Mapping, 2015, 36, 3516-3527.	1.9	34
183	Predicting Progression from Cognitive Impairment to Alzheimer's Disease with the Disease State Index. Current Alzheimer Research, 2015, 12, 69-79.	0.7	22
184	Orbitofrontal <sup><b>18</b></sup> F-DOPA Uptake and Movement Preparation in Parkinson's Disease. Parkinson's Disease, 2015, 2015, 1-7.	0.6	6
185	A normative study of the Italian printed word version of the free and cued selective reminding test. Neurological Sciences, 2015, 36, 1127-1134.	0.9	21
186	P2-188: Characterization of cognitive function with the cantab in individuals with amnestic mild cognitive impairment in relation to hippocampal volume, amyloid, and tau status: Preliminary baseline results from the PharmaCog/european-ADNI study. , 2015, 11, P564-P564.		2
187	DT-02-03: A randomized, controlled, multicenter, international study of the impact of florbetapir (18) Tj ETQq1	0.784314	4 rgBT /Over
188	Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. NeuroImage: Clinical, 2015, 7, 34-42.	1.4	85
189	Occipital sources of resting-state alpha rhythms are related to local gray matter density in subjects with amnesic mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2015, 36, 556-570.	1.5	93
190	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	3.7	284
191	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	1.5	30
192	Neuroimaging features inC9orf72andTARDBPdouble mutation with FTD phenotype. Neurocase, 2015, 21, 529-534.	0.2	8
193	Brain 18F-DOPA PET and cognition in de novo Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1062-1070.	3.3	23
194	Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Neurological Sciences, 2015, 36, 1075-1081.	0.9	35
195	Nigro-caudate dopaminergic deafferentation: a marker of REM sleep behavior disorder?. Neurobiology of Aging, 2015, 36, 3300-3305.	1.5	63
196	Bilateral motor and premotor cortex hypometabolism in a case of Mills syndrome. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 414-417.	1.1	6
197	Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnestic MCI: An European Alzheimer's Disease Consortium (EADC) Project. Journal of Alzheimer's Disease, 2015, 44, 815-826.	1.2	67
198	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.4	56

#	Article	IF	CITATIONS
199	Screening of Early and Late Onset Alzheimer's Disease Genetic Risk Factors in a Cohort of Dementia Patients from Liguria, Italy. Current Alzheimer Research, 2015, 12, 802-812.	0.7	6
200	Amyloid positron emission tomography and cognitive reserve. World Journal of Radiology, 2015, 7, 475.	0.5	8
201	Erratum to "A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis― BioMed Research International, 2014, 2014, 1-1.	0.9	35
202	Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology, 2014, 83, 1067-1074.	1.5	154
203	Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage: Clinical, 2014, 6, 445-454.	1.4	172
204	Cortical sources of resting state electroencephalographic alpha rhythms deteriorate across time in subjects with amnesic mild cognitive impairment. Neurobiology of Aging, 2014, 35, 130-142.	1.5	61
205	The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 844-852.	3.3	103
206	Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 764-775.	3.3	30
207	Recommendations of the Sleep Study Group of the Italian Dementia Research Association (SINDem) on clinical assessment and management of sleep disorders in individuals with mild cognitive impairment and dementia: a clinical review. Neurological Sciences, 2014, 35, 1329-1348.	0.9	25
208	Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects. NeuroImage, 2014, 101, 390-403.	2.1	99
209	Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1938-1946.	3.3	60
210	Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. Alzheimer's and Dementia, 2014, 10, 456-467.	0.4	16
211	Association of central serotonin transporter availability and body mass index in healthy Europeans. European Neuropsychopharmacology, 2014, 24, 1240-1247.	0.3	34
212	Metabolic Correlates of Rey Auditory Verbal Learning Test in Elderly Subjects with Memory Complaints. Journal of Alzheimer's Disease, 2014, 39, 103-113.	1.2	39
213	O4-07-05: ADDED VALUE OF MRI BIOMARKERS TO NEUROPSYCHOLOGICAL TEST PERFORMANCE FOR PREDICTION OF AD IN SUBJECTS WITH MCI. , 2014, 10, P265-P265.		1
214	P3-101: CROSS-SECTIONAL BIOMARKER CHARACTERIZATION OF MILD COGNITIVE IMPAIRMENT PATIENTS IN WP5 PHARMACOG/E-ADNI STUDY. , 2014, 10, P665-P665.		1
215	P1-216: FRONTAL CORTICAL SOURCES OF AUDITORY ODDBALL EVENT-RELATED POTENTIALS ARE RELATED TO CEREBROSPINAL FLUID Î <sup>2</sup> AMYLOID IN AMNESTIC MCI SUBJECTS. , 2014, 10, P383-P383.		0

216 Neuroimaging Findings in Mild Cognitive Impairment. , 2014, , 271-307.

#	Article	IF	CITATIONS
217	Cognitive reserve and clinical expression of Alzheimer's disease: evidence and implications for brain PET imaging. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 239-47.	1.0	13
218	No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [1231]FP-CIT (DaTSCAN) and SPECT. EJNMMI Research, 2013, 3, 39.	1.1	21
219	European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 213-227.	3.3	198
220	Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1122-1125.	3.3	13
221	Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 565-573.	3.3	86
222	Resting metabolic connectivity in Alzheimer's disease. Clinical and Translational Imaging, 2013, 1, 271-278.	1.1	9
223	Cortical Sources of Resting State EEG Rhythms are Sensitive to the Progression of Early Stage Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 1015-1035.	1.2	72
224	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. Neurobiology of Aging, 2013, 34, 2003-2013.	1.5	86
225	Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology, 2013, 80, 1124-1132.	1.5	110
226	Value of Semiquantitative Analysis for Clinical Reporting of 123I-2-β-Carbomethoxy-3β-(4-Iodophenyl)-N-(3-Fluoropropyl)Nortropane SPECT Studies. Journal of Nuclear Medicine, 2013, 54, 714-722.	2.8	62
227	Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. Journal of Nuclear Medicine, 2013, 54, 894-902.	2.8	108
228	Brain morphometry reproducibility in multi-center 3T MRI studies: A comparison of cross-sectional and longitudinal segmentations. NeuroImage, 2013, 83, 472-484.	2.1	157
229	No association between striatal dopamine transporter binding and body mass index: A multi-center European study in healthy volunteers. NeuroImage, 2013, 64, 61-67.	2.1	47
230	The Association Between APOE ε4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of Alzheimer's Disease, 2013, 35, 241-246.	1.2	7
231	Summary Metrics to Assess Alzheimer Disease–Related Hypometabolic Pattern with <sup>18</sup> F-FDG PET: Head-to-Head Comparison. Journal of Nuclear Medicine, 2012, 53, 592-600.	2.8	79
232	Prevalence of Sleep Disturbances in Mild Cognitive Impairment and Dementing Disorders: A Multicenter Italian Clinical Cross-Sectional Study on 431 Patients. Dementia and Geriatric Cognitive Disorders, 2012, 33, 50-58.	0.7	265
233	The Short Cognitive Evaluation Battery in Cognitive Disorders of the Elderly – Italian Version. Dementia and Geriatric Cognitive Disorders, 2012, 33, 255-265.	0.7	3
234	The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. Neurobiology of Aging, 2012, 33, 201.e1-201.e8.	1.5	48

#	Article	IF	CITATIONS
235	What predicts cognitive decline in de novo Parkinson's disease?. Neurobiology of Aging, 2012, 33, 1127.e11-1127.e20.	1.5	34
236	Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiology of Aging, 2012, 33, 2533-2550.	1.5	108
237	Alzheimer's disease markers from structural MRI and FDG-PET brain images. European Physical Journal Plus, 2012, 127, 1.	1.2	15
238	A repository based on a dynamically extensible data model supporting multidisciplinary research in neuroscience. BMC Medical Informatics and Decision Making, 2012, 12, 115.	1.5	10
239	Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 251-259.	3.3	148
240	The impact of molecular imaging in the management of movement disorders: an ongoing revolution. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2012, 56, 1-3.	0.4	16
241	Correlation between Doppler Velocities and Duplex Ultrasound Carotid Cross-sectional Percent Stenosis. Academic Radiology, 2011, 18, 1485-1491.	1.3	6
242	Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease. NeuroImage, 2011, 58, 469-480.	2.1	161
243	Radionuclide brain imaging correlates of cognitive impairment in Parkinson's disease (PD). Journal of the Neurological Sciences, 2011, 310, 31-35.	0.3	19
244	Assessment of dementia in ethnic minority patients in Europe: a European Alzheimer's Disease Consortium survey. International Psychogeriatrics, 2011, 23, 86-95.	0.6	104
245	Seizures Can Precede Cognitive Symptoms in Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 737-742.	1.2	21
246	Do Instrumental Activities of Daily Living Predict Dementia at 1†and 2â€Year Followâ€Up? Findings from the Development of Screening Guidelines and Diagnostic Criteria for Predementia <scp>A</scp> lzheimer's Disease Study. Journal of the American Geriatrics Society, 2011, 59, 2273-2281.	1.3	59
247	Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2209-2218.	3.3	32
248	Diagnostic criteria for apathy in clinical practice. International Journal of Geriatric Psychiatry, 2011, 26, 158-165.	1.3	182
249	Stability of clinical condition in mild cognitive impairment is related to cortical sources of alpha rhythms: An electroencephalographic study. Human Brain Mapping, 2011, 32, 1916-1931.	1.9	41
250	Regional Differences in Effects of <i>APOE</i> Îμ4 on Cognitive Impairment in Non-Demented Subjects. Dementia and Geriatric Cognitive Disorders, 2011, 32, 135-142.	0.7	18
251	Whole Body and Cardiac Metaiodobenzylguanidine Kinetics in Parkinson Disease and Multiple System Atrophy. Clinical Nuclear Medicine, 2010, 35, 311-316.	0.7	7
252	Unawareness of Memory Deficit in Amnestic MCI: FDG-PET Findings. Journal of Alzheimer's Disease, 2010, 22, 993-1003.	1.2	59

#	Article	IF	CITATIONS
253	Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 36-45.	3.3	95
254	EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 434-442.	3.3	56
255	EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 443-450.	3.3	263
256	FDC-PET for early assessment of Alzheimer's disease: isn't the evidence base large enough?. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1604-1609.	3.3	12
257	Cognitiveâ€nigrostriatal relationships in de novo, drugâ€naÃ⁻ve Parkinson's disease patients: A [lâ€123]FP IT SPECT study. Movement Disorders, 2010, 25, 35-43.	2.2	83
258	Impaired access to semantic memory for the cognition of geographic space in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2010, 50, 198-201.	1.4	2
259	Metabolic Compensation and Depression in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2010, 29, 37-45.	0.7	18
260	The Reversed Clock Drawing Test Phenomenon in Alzheimer's Disease: A Perfusion SPECT Study. Dementia and Geriatric Cognitive Disorders, 2010, 29, 1-10.	0.7	8
261	MCI Patients Declining and Not-Declining at Mid-Term Follow-Up: FDG-PET Findings. Current Alzheimer Research, 2010, 7, 287-294.	0.7	41
262	Functional compensation in incipient Alzheimer's disease. Neurobiology of Aging, 2010, 31, 387-397.	1.5	28
263	Cortical sources of resting EEG rhythms in mild cognitive impairment and subjective memory complaint. Neurobiology of Aging, 2010, 31, 1787-1798.	1.5	97
264	White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1069-1074.	0.9	39
265	Principal component analysis in mild and moderate Alzheimer's disease — A novel approach to clinical diagnosis. Psychiatry Research - Neuroimaging, 2009, 173, 8-14.	0.9	35
266	Traditional and non traditional risk factors in accelerated atherosclerosis in Systemic Lupus Erythematosus: Role of vascular endothelial growth factor (VEGATS Study). Autoimmunity Reviews, 2009, 8, 309-315.	2.5	54
267	Amnestic mild cognitive impairment in Parkinson's disease: A brain perfusion SPECT study. Movement Disorders, 2009, 24, 414-421.	2.2	63
268	EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 2103-2110.	3.3	469
269	EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 2093-2102.	3.3	143
270	The factorial structure of the mini mental state examination (MMSE) in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2009, 49, 180-185.	1.4	34

#	Article	IF	CITATIONS
271	Directionality of EEG synchronization in Alzheimer's disease subjects. Neurobiology of Aging, 2009, 30, 93-102.	1.5	132
272	Automatic analysis of medial temporal lobe atrophy from structural MRIs for the early assessment of Alzheimer disease. Medical Physics, 2009, 36, 3737-3747.	1.6	39
273	SPECT Predictors of Cognitive Decline and Alzheimer's Disease in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2009, 17, 761-772.	1.2	42
274	Global Functional Coupling of Resting EEG Rhythms is Abnormal in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Psychophysiology, 2009, 23, 224-234.	0.3	27
275	Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2191-2202.	3.3	77
276	Brain SPECT in subtypes of mild cognitive impairment. Journal of Neurology, 2008, 255, 1344-1353.	1.8	54
277	Consistency of Neuropsychiatric Syndromes across Dementias: Results from the European Alzheimer Disease Consortium. Dementia and Geriatric Cognitive Disorders, 2008, 25, 1-8.	0.7	167
278	Patient and Caregiver Perspectives of Quality of Life in Dementia. Dementia and Geriatric Cognitive Disorders, 2008, 26, 138-146.	0.7	151
279	Multi-Center Comparison of Medial Temporal Atrophy in Patients with Alzheimer's Disease – Data from the ICTUS Study. Dementia and Geriatric Cognitive Disorders, 2008, 26, 314-322.	0.7	8
280	Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer's Disease. Neuroepidemiology, 2008, 30, 254-265.	1.1	86
281	Automatic Localization of the Hippocampal Region in MR Images to Asses Early Diagnosis of Alzheimer's Disease in MCI Patients. , 2008, , .		1
282	Mitochondrial Function Is Related to Alterations at Brain SPECT in Depressed Patients. CNS Spectrums, 2008, 13, 805-814.	0.7	24
283	The need of appropriate brain SPECT templates for SPM comparisons. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2008, 52, 89-98.	0.4	15
284	Neuropsychiatric Syndromes in Dementia. Dementia and Geriatric Cognitive Disorders, 2007, 24, 457-463.	0.7	305
285	CLUSTERING OF BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA (BPSD): A EUROPEAN ALZHEIMER'S DISEASE CONSORTIUM (EADC) STUDY. Acta Clinica Belgica, 2007, 62, 426-432.	0.5	88
286	Cortical sources of awake scalp EEG in eating disorders. Clinical Neurophysiology, 2007, 118, 1213-1222.	0.7	23
287	Resting EEG sources correlate with attentional span in mild cognitive impairment and Alzheimer's disease. European Journal of Neuroscience, 2007, 25, 3742-3757.	1.2	101
288	Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1071-1081.	3.3	34

#	Article	IF	CITATIONS
289	The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1240-1253.	3.3	97
290	Brain perfusion correlates of medial temporal lobe atrophy and white matter hyperintensities in mild cognitive impairment. Journal of Neurology, 2007, 254, 1000-1008.	1.8	36
291	Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment. Journal of Neurology, 2007, 254, 1698-1707.	1.8	81
292	99mTc-HMPAO and 99mTc-ECD brain uptake correlates of verbal memory in Alzheimer's disease. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2007, 51, 357-63.	0.4	12
293	Donepezil effects on sources of cortical rhythms in mild Alzheimer's disease: Responders vs. Non-Responders. NeuroImage, 2006, 31, 1650-1665.	2.1	97
294	Sources of cortical rhythms change as a function of cognitive impairment in pathological aging: a multicenter study. Clinical Neurophysiology, 2006, 117, 252-268.	0.7	260
295	Frontal white matter volume and delta EEG sources negatively correlate in awake subjects with mild cognitive impairment and Alzheimer's disease. Clinical Neurophysiology, 2006, 117, 1113-1129.	0.7	150
296	Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 714-718.	0.9	539
297	Fronto-parietal coupling of brain rhythms in mild cognitive impairment: A multicentric EEG study. Brain Research Bulletin, 2006, 69, 63-73.	1.4	159
298	Stimulating or conventional perineural catheters after hallux valgus repair: a double-blind, pharmaco-economic evaluation. Acta Anaesthesiologica Scandinavica, 2006, 50, 1284-1289.	0.7	20
299	Allogeneic bone marrow transplantation (BMT) for refractory Behçet's disease with severe CNS involvement. Bone Marrow Transplantation, 2006, 37, 1061-1063.	1.3	34
300	The Von Restorff effect in ageing and Alzheimer's disease. Neurological Sciences, 2006, 27, 166-172.	0.9	15
301	Sources of cortical rhythms in adults during physiological aging: A multicentric EEG study. Human Brain Mapping, 2006, 27, 162-172.	1.9	253
302	Fusion of the MR image to SPECT with possible correction for partial volume effects. IEEE Transactions on Nuclear Science, 2006, 53, 189-197.	1.2	10
303	Migraine during systemic lupus erythematosus: findings from brain single photon emission computed tomography. Journal of Rheumatology, 2006, 33, 2184-91.	1.0	5
304	Stroop interference task and single-photon emission tomography in anorexia: A preliminary report. International Journal of Eating Disorders, 2005, 38, 323-329.	2.1	20
305	Global cognitive impairment should be taken into account in SPECT–neuropsychology correlations: the example of verbal memory in very mild Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1186-1192.	3.3	10
306	Toward the Validation of Functional Neuroimaging as a Potential Biomarker for Alzheimer?s Disease: Implications for Drug Development. Molecular Imaging and Biology, 2005, 7, 59-68.	1.3	17

#	Article	IF	CITATIONS
307	White matter hyperintensities on brain magnetic resonance in systemic sclerosis. Annals of the Rheumatic Diseases, 2005, 64, 777-779.	0.5	29
308	Resting SPECT-neuropsychology correlation in very mild Alzheimer's disease. Clinical Neurophysiology, 2005, 116, 364-375.	0.7	51
309	Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. European Psychiatry, 2005, 20, 490-496.	0.1	177
310	Abnormal fronto-parietal coupling of brain rhythms in mild Alzheimer's disease: a multicentric EEG study. European Journal of Neuroscience, 2004, 19, 2583-2590.	1.2	137
311	Right hemispheric dysfunction in a case of pure progressive aphemia: fusion of multimodal neuroimaging. Psychiatry Research - Neuroimaging, 2004, 130, 97-107.	0.9	8
312	Predicting the accuracy of a diagnosis of Alzheimer's disease with 99mTc HMPAO single photon emission computed tomography. Psychiatry Research - Neuroimaging, 2004, 131, 157-168.	0.9	17
313	Quantitative EEG and perfusional single photon emission computed tomography correlation during long-term donepezil therapy in Alzheimer's disease. Clinical Neurophysiology, 2004, 115, 39-49.	0.7	47
314	Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. European Journal of Haematology, 2004, 72, 113-120.	1.1	28
315	Cortical alpha rhythms in mild Alzheimer's disease. A multicentric EEG study. International Congress Series, 2004, 1270, 44-49.	0.2	3
316	Individual analysis of EEG frequency and band power in mild Alzheimer's disease. Clinical Neurophysiology, 2004, 115, 299-308.	0.7	311
317	Mapping distributed sources of cortical rhythms in mild Alzheimer's disease. A multicentric EEG study. NeuroImage, 2004, 22, 57-67.	2.1	253
318	99m Tc-HMPAO and 99m Tc-ECD perform differently in typically hypoperfused areas in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1009-1013.	3.3	22
319	Psychological and social aspects in management of Alzheimer's patients: an inquiry among caregivers. Neurological Sciences, 2003, 24, 329-335.	0.9	21
320	Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1371-1381.	0.9	69
321	Voxel-Based Approaches in Clinical Imaging. , 2003, 22, 72-85.		4
322	Quantitative EEG Changes in Alzheimer Patients during Long-Term Donepezil Therapy. Neuropsychobiology, 2002, 46, 49-56.	0.9	77
323	Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clinical Neurophysiology, 2002, 113, 1241-1248.	0.7	89
324	Statistical Parametric Mapping of 99mTc-HMPAO-SPECT Images for the Diagnosis of Alzheimer's Disease: Normalizing to Cerebellar Tracer Uptake. NeuroImage, 2002, 17, 1193-1202.	2.1	106

#	Article	IF	CITATIONS
325	Duplex scanning of neck vessels: need for extending the consensus on indications. Neurological Sciences, 2002, 22, 437-441.	0.9	10
326	Brain Functional Involvement by Perfusion SPECT in Systemic Sclerosis and Behçet's Disease. Annals of the New York Academy of Sciences, 2002, 966, 409-414.	1.8	25
327	Carotid Atherosclerosis in Patients with Rheumatoid Arthritis. Annals of the New York Academy of Sciences, 2002, 966, 478-482.	1.8	14
328	Spinal block or total intravenous anaesthesia with propofol and remifentanil for gynaecological outpatient procedures. European Journal of Anaesthesiology, 2002, 19, 594-599.	0.7	9
329	Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. Journal of Nuclear Medicine, 2002, 43, 983-90.	2.8	77
330	Hemispheric dominance evaluation by FMRI in pharmaco-resistant epilepsy. NeuroImage, 2001, 13, 851.	2.1	0
331	Clinical correlative evaluation of an iterative method for reconstruction of brain SPECT images. Nuclear Medicine and Biology, 2001, 28, 627-632.	0.3	9
332	Using SPM as a diagnostic help with HMPAO-SPECT in Alzheimer's disease. NeuroImage, 2001, 13, 1044.	2.1	191
333	Enhancement of SPECT reconstructions by means of coregistered MR data. IEEE Transactions on Nuclear Science, 2001, 48, 750-755.	1.2	7
334	Relationships between cortisol, dehydroepiandrosterone sulphate and insulin-like growth factor-I system in dementia. Journal of Endocrinological Investigation, 2001, 24, 139-146.	1.8	68
335	Regional Cerebral Blood Flow and Prognostic Evaluation in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2001, 12, 89-97.	0.7	22
336	Pulsatile electrical impedance response from cerebrally dead adult patients is not a reliable tool for detecting cerebral perfusion changes. Physiological Measurement, 2001, 22, 341-349.	1.2	9
337	Brain perfusion spect in juvenile neuro-Behçet's disease. Journal of Nuclear Medicine, 2001, 42, 1151-7.	2.8	14
338	Studio RMf della dominanza emisferica in destrimani e non destrimani. The Neuroradiology Journal, 2000, 13, 131-138.	0.1	1
339	Evidence of cerebral hypoperfusion in scleroderma patients. Rheumatology, 2000, 39, 1366-1373.	0.9	56
340	Hippocampal Perfusion and Pituitary-Adrenal Axis in Alzheimer's Disease. Neuropsychobiology, 2000, 42, 51-57.	0.9	39
341	Hippocampal perfusion in mild Alzheimer's disease. Psychiatry Research - Neuroimaging, 2000, 100, 65-74.	0.9	76
342	Dexamethasone effects on cortisol secretion in Alzheimer's disease: Some clinical and hormonal features in suppressor and nonsuppressor patients. Journal of Endocrinological Investigation, 2000, 23, 178-186.	1.8	27

#	Article	IF	CITATIONS
343	Morning increase of whole blood viscosity in obstructive sleep apnea syndrome. Clinical Hemorheology and Microcirculation, 2000, 22, 21-7.	0.9	71
344	EEG spectral profile to stage Alzheimer's disease. Clinical Neurophysiology, 1999, 110, 1831-1837.	0.7	124
345	Timing of Disease Progression by Quantitative EEG in Alzheimer's Patients. Journal of Clinical Neurophysiology, 1999, 16, 566.	0.9	42
346	99mTc-HMPAO regional cerebral blood flow and quantitative electroencephalography in Alzheimer's disease: a correlative study. Journal of Nuclear Medicine, 1999, 40, 522-9.	2.8	71
347	Long-term effects of boxing and judo-choking techniques on brain function. Italian Journal of Neurological Sciences, 1998, 19, 367-372.	0.1	22
348	Feasibility in the clinical setting of perfusion brain SPECT imaging employing a brain-dedicated gamma camera and the conjugate gradients with modified matrix reconstruction method. Italian Journal of Neurological Sciences, 1998, 19, 373-377.	0.1	3
349	Relationships between s99mTc-HMPAO ceraspect and quantitative EEG observations in Alzheimer's disease. Archives of Gerontology and Geriatrics, 1998, 26, 363-368.	1.4	17
350	Quantitative Electroencephalography and Regional Cerebral Blood Flow: Discriminant Analysis between Alzheimer's Patients and Healthy Controls. Dementia and Geriatric Cognitive Disorders, 1998, 9, 274-283.	0.7	66
351	Impaired quantitative cerebral blood flow in scleroderma patients. Journal of the Neurological Sciences, 1997, 152, 63-71.	0.3	37
352	Neurophysiological asymmetries in Alzheimer's disease. Electroencephalography and Clinical Neurophysiology, 1997, 103, 134.	0.3	1
353	Prognostic significance of quantitative electroencephalography in Alzheimer patients: preliminary observations. Electroencephalography and Clinical Neurophysiology, 1996, 99, 123-128.	0.3	29
354	Cerebral blood flow reserve in patients with syndrome X. Coronary Artery Disease, 1996, 7, 587-590.	0.3	4
355	Cerebral haemodynamic changes induced by spinal cord stimulation in man. Italian Journal of Neurological Sciences, 1996, 17, 55-57.	0.1	18
356	57. Nocturnal sleep increases plasma fibrinogen in Sleep Apnoea Syndrome. Fibrinolysis, 1996, 10, 18.	0.5	0
357	Accuracy of 133-xenon regional cerebral blood flow and quantitative electroencephalography in systemic lupus erythematosus. Lupus, 1996, 5, 93-102.	0.8	10
358	Cerebral hyperperfusion antedates by years strokelike episodes in the MELAS syndrome. Stroke, 1996, 27, 341-2.	1.0	2
359	Assessment of regional cerebral blood flow during spinal cord stimulation in humans. Stereotactic and Functional Neurosurgery, 1995, 64, 197-201.	0.8	18
360	Cerebral Blood Flow and Somatosensory Evoked Response Changes Induced by Spinal Cord Stimulation: Preliminary Follow-Up Observations. Stereotactic and Functional Neurosurgery, 1994, 62, 179-185.	0.8	12

#	Article	IF	CITATIONS
361	Blood viscosity and cerebral blood flow Stroke, 1994, 25, 910-911.	1.0	Ο
362	Regional cerebral blood flow in familial hypercholesterolemia Stroke, 1994, 25, 831-836.	1.0	17
363	Regional Cerebral Blood Flow and Cerebrovascular Reactivity in IDDM. Diabetes Care, 1993, 16, 462-468.	4.3	52
364	Regional cerebral blood flow in chronic hypertension. A correlative study Stroke, 1993, 24, 1148-1153.	1.0	129
365	Regional cerebral blood flow in chronic stroke patients Stroke, 1993, 24, 94-99.	1.0	37
366	Fibrinogen and cerebral blood flow: A correlative study. Clinical Hemorheology and Microcirculation, 1993, 13, 245-252.	0.9	0
367	Correlates of contralateral hypoperfusion in chronic stroke patients. Neurological Research, 1992, 14, 125-126.	0.6	1
368	Brain functional imaging in senile psychopathology. International Journal of Psychophysiology, 1991, 10, 271-280.	0.5	8
369	Does Today's Vaginal Surgery Still Have a Specific Role in the Treatment of Endometrial Cancer?. Annals of the New York Academy of Sciences, 1991, 622, 477-484.	1.8	6
370	Hemorheological and cerebral blood flow changes induced by LDL-apheresis in familial hypercholesterolemic patients. Clinical Hemorheology and Microcirculation, 1991, 11, 9-18.	0.9	0
371	Effects of Betaâ€Adrenoreceptor Antagonists on Cerebral Blood Flow of Cirrhotic Patients with Portal Hypertension. Journal of Clinical Pharmacology, 1991, 31, 136-139.	1.0	6
372	Regional cerebral blood flow asymmetries in a group of 189 normal subjects at rest. Brain Topography, 1991, 4, 57-63.	0.8	13
373	Spinal cord stimulation and cerebral haemodynamics. Acta Neurochirurgica, 1991, 111, 43-48.	0.9	54
374	CBF side-to-side asymmetries in stenosis-occlusion of internal carotid artery. Relevance of CT findings and collateral supply. Italian Journal of Neurological Sciences, 1991, 12, 383-388.	0.1	6
375	Judo and choking: EEG and regional cerebral blood flow findings. Journal of Sports Medicine and Physical Fitness, 1991, 31, 605-10.	0.4	7
376	High-pressure hemarthrosis: possible consequences to the vascularization of the femoral head. Italian Journal of Orthopaedics and Traumatology, 1991, 17, 533-45.	0.0	2
377	Phosphatidylserine: Quantitative EEG Effects in Healthy Volunteers. Neuropsychobiology, 1990, 24, 42-48.	0.9	12
378	Primary dysautonomia: cerebral blood flow and hemodynamic findings. Case report Italian Journal of Neurological Sciences, 1990, 11, 281-288.	0.1	0

#	Article	IF	CITATIONS
379	An atypical paediatric case of malignant atrophic papulosis (Köhlmeier-Degos disease). European Journal of Pediatrics, 1990, 149, 457-458.	1.3	12
380	Multiple effects of LDL-apheresis against progression of atherosclerosis in patients with familial hypercholesterolemia. , 1990, , 506-513.		0
381	Acute effects of acetyl-L-carnitine on regional cerebral blood flow in patients with brain ischaemia. International Journal of Clinical Pharmacology Research, 1990, 10, 123-8.	0.4	6
382	Cerebral blood flow and plasma free tryptophan in cirrhotics with and without hepatic encephalopathy. Italian Journal of Neurological Sciences, 1989, 10, 415-421.	0.1	8
383	Regional Cerebral Blood Flow and Anxiety: A Correlation Study in Neurologically Normal Patients. Journal of Cerebral Blood Flow and Metabolism, 1989, 9, 410-416.	2.4	24
384	Evaluation of cerebral blood flow data in stroke patients using a mapping system Stroke, 1989, 20, 1182-1189.	1.0	7
385	Cerebral blood flow recovery after reserpine withdrawal. Italian Journal of Neurological Sciences, 1988, 9, 403-404.	0.1	1
386	Regional cerebral blood flow in essential hypertension: data evaluation by a mapping system Stroke, 1987, 18, 13-20.	1.0	79
387	Reduction of Cerebral Blood Flow in Subclinical Hepatic Encephalopathy and its Correlation with Plasma-Free Tryptophan. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 768-772.	2.4	37
388	Transfreq: A Python package for computing the thetaâ€ŧoâ€alpha transition frequency from resting state electroencephalographic data. Human Brain Mapping, 0, , .	1.9	1